Identification of novel blood-based signatures of neurodegenerative disease using high-sensitivity NULISA protein assays

Featuring:

Maura Malpetti, PhD

UK DRI Emerging Leader
Race Against Dementia ARUK Fellow
Senior Research Associate
University of Cambridge

 

Sterling Johnson, PhD

Professor of Geriatrics and Dementia,
Department of Geriatrics and Gerontology,
University of Wisconsin
Watch On Demand

Join us for an insightful webinar exploring cutting-edge advancements in blood-based biomarker research for neurodegenerative diseases. Dr. Maura Malpetti and Dr. Sterling Johnson will present novel findings leveraging Alamar Biosciences’ highly sensitive NULISA™ immunoassay technology. This session will cover how multiplex proteomic analysis is unlocking new insights into Alzheimer’s disease (AD) and other neurodegenerative disorders, providing crucial data for early detection, differential diagnosis, and disease monitoring. The discussion will highlight Cambridge-based cohorts as well as the Wisconsin Registry for Alzheimer’s Prevention (WRAP) study, showcasing how blood biomarkers, including pTau, NfL, and inflammation markers, are reshaping our understanding of AD progression, multi-etiology dementia, and survival prediction.

Dr. Malpetti will discuss the role of inflammation and neurodegeneration in diseases beyond AD, including frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP). Meanwhile, Dr. Johnson will delve into the challenges of identifying mixed-pathology dementia and how emerging biomarker tools enhance precision medicine approaches. Attendees will gain insights into the translational impact of large-scale proteomic screening, the integration of blood-based markers with imaging modalities, and the future of biomarker-driven clinical trials. Additionally, Doug Hinerfeld, Sr. Director of Field Application Support, will provide an overview of Alamar’s innovative NULISA technology and its role in accelerating discoveries in neurodegenerative research.

Register Now
Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.